ArticleWorld journal of nuclear medicine
Clinical effectiveness of (18)f-fluorodeoxyglucose positron emission tomography/computed tomography in management of renal cell carcinoma: a single institution experience.
Article in World journal of nuclear medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0.Journal for immunotherapy of cancer · 2026Guideline
- Pre-operative imaging evaluation of renal cell carcinoma.Revista da Associacao Medica Brasileira (1992) · 2024Guideline
- Diagnostic performance of MRI, SPECT, and PET in detecting renal cell carcinoma: a systematic review and meta-analysis.BMC cancer · 2022Pooled it
- Clear cell renal carcinoma metastasis to the thyroid gland combined with papillary thyroid carcinoma - a case report.Frontiers in oncology · 2025Article
- Role of 18F-FDG PET/CT for detection of recurrence and metastases in renal cell carcinoma-are we underusing PET/CT?Diagnostic and interventional radiology (Ankara, Turkey) · 2022Article
- A Five Collagen-Related Gene Signature to Estimate the Prognosis and Immune Microenvironment in Clear Cell Renal Cell Cancer.Vaccines · 2021Article
- Clinical utility of FDG PET/CT for primary and recurrent papillary renal cell carcinoma.Cancer imaging : the official publication of the International Cancer Imaging Society · 2021Article
- Impact of PET/CT for Assessing Response to Immunotherapy-A Clinical Perspective.Journal of clinical medicine · 2020Review
- Imaging for Metastatic Renal Cell Carcinoma.The Urologic clinics of North America · 2020Review
- Renal Cell Carcinoma Ablation: Preprocedural, Intraprocedural, and Postprocedural Imaging.Radiology. Imaging cancer · 2019Review
- Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma.Current urology reports · 2019Review
- Imaging tumour thrombus of clear cell renal cell carcinoma: FDG PET or PSMA PET? Direct in vivo comparison of two technologies.Urology case reports · 2018Article
- Advances in medical imaging for the diagnosis and management of common genitourinary cancers.Urologic oncology · 2017Review
- Update on advances in molecular PET in urological oncology.Japanese journal of radiology · 2016Review
- The Place of FDG PET/CT in Renal Cell Carcinoma: Value and Limitations.Frontiers in oncology · 2016Review
- Role of positron emission tomography/computed tomography in the evaluation of renal cell carcinoma.Indian journal of urology : IJU : journal of the Urological Society of IndiaReview
- PET-CT and PET-MR in urological cancers other than prostate cancer: An update on state of the art.Indian journal of urology : IJU : journal of the Urological Society of IndiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Positron emission tomography (PET) is currently the most advanced technique of metabolic imaging available for tumor diagnosis and follow-up. The aim of this study was to examine the versatility and accuracy of fluorodeoxyglucose (FDG) PET/computed tomography (CT) in the metastasis detection of renal cell carcinoma (RCC). We also compared our findings to other similar studies from the literature. This is the biggest study so far to examine the sensitivity and specificity of FDG PET/CT in the management of RCC. A retrospective review was carried out on all the FDG PET/CT studies done from January 1999 to January 2014 at our institution. Biopsy results were considered the gold standard. For our patients (n = 315) with biopsy results, FDG PET/CT studies exhibited 100% sensitivity, 100% specificity. Our results were better than results achieved by other studies. The use of FDG PET/CT in restaging and metastasis detection of RCC has many advantages, in addition to high accuracy. This imaging technique has great potential in influencing treatment decisions. We recommend the incorporation of FDG PET/CT in routine standard protocols for RCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.